November 16, 2009 (FinancialWire) — Clinical research organization Encorium Group, Inc. (NASDAQ: ENCO) has appointed Sari Laitinen to its board. Laitinen will replace Jyrki Mattila, who has resigned from the company’s board.

Laitinen is the founder and owner of Sari Laitinen, US Legal Counsel, a legal services firm established in 2006 in Espoo, Finland. Prior to 2006, she served as director of U.S. capital markets with Helsinki-based Ernst & Young Oy.

As an Encorium director, Laitinen will serve as the chair of the board’s nominating committee and as a member of the audit and executive compensation committees.

With the appointment of Laitinen, Encorium’s board will remain at five members and will consist of a majority of independent directors.

Berwyn, Pennsylvania-based Encorium Group specializes in the design and management of clinical trials and patient registries for the pharmaceutical, biotechnology and medical device industries.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports, filings and conference call webcasts for companies mentioned in the news are available via Investrend Syndications (http://investrend.ar.wilink.com/?level=279). Friday’s issued reports and/or recorded webcasts include Yanglin Soybean Inc. (OTCBB: YSYB), J.C. Penney (NYSE: JCP), Penford Corporation (NASDAQ: PENX), Savanna Energy Services Corp. (TSX: SVY) and ZAGG Inc. (NASDAQ: ZAGG).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.